Omeros Logo     Print Page  |  Close Window

2016 Press Releases

E-mail Alerts Receive E-mail Alerts | RSS RSS Feeds
Keyword Search
 
2016 | 2015 | 2014 | 2013 | 2012 | 2011
DateTitle  
12/06/16Omeros Extending Compassionate Use for Pediatric Patient No Longer Requiring Dialysis after OMS721 Treatment
-- 15 Year-Old with Stem Cell Transplant-Associated TMA Had Previously Developed Additional Life-Threatening Condition while on Soliris® -- SEATTLE--(BUSINESS WIRE)--Dec. 6, 2016-- Omeros Corporation (NASDAQ: OMER) today announced that, following physician request, it will provide continued supply of OMS721 for a pediatric patient with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) who is currently receivin... 
 Printer Friendly Version
12/05/16Omeros’ Proprietary Orphan GPCR Program Delivers New Target and Approach in Cancer Immunotherapy
-- Small-Molecule Inhibitors Enhance Immune System and May Offer Advantages over Existing Cancer Therapies -- SEATTLE--(BUSINESS WIRE)--Dec. 5, 2016-- Omeros Corporation (NASDAQ: OMER) today announced that its small-molecule inhibitors against GPR174, an orphan G protein-coupled receptor (GPCR) narrowly expressed in immune cells and linked to cancers, substantially and statistically significantly boost levels of cytokines and reduce the popula... 
 Printer Friendly Version
11/30/16International Consortium of Complement Experts Receives €1.3 Million Grant to Study Role of MASP-2 and Lectin Pathway in Traumatic Brain Injury
-- NEURON-Funded Program Will Evaluate Benefits of Omeros’ MASP-2 Antibody -- SEATTLE--(BUSINESS WIRE)--Nov. 30, 2016-- Omeros Corporation (NASDAQ: OMER) today announced that an international consortium of complement experts from Italy, United Kingdom, Germany, Spain and Poland was awarded €1.3 million in grant funding to study the benefits of inhibiting mannan-binding lectin-associated serine protease-2 (MASP-2) and the lectin pathway in trau... 
 Printer Friendly Version
11/21/16Omeros Announces Successful Outcome of OMIDRIA® Pediatric Cataract Trial
-- Six-Month Extension of Patent Exclusivity and Label Expansion Expected -- SEATTLE--(BUSINESS WIRE)--Nov. 21, 2016-- Omeros Corporation (NASDAQ: OMER) today announced the successful outcome of its recently completed post-marketing clinical trial of the effect of OMIDRIA® (phenylephrine and ketorolac injection) 1% / 0.3% in pediatric patients undergoing cataract surgery. OMIDRIA is approved by the FDA for use in adult patients undergoing cata... 
 Printer Friendly Version
11/10/16Single Dose of Omeros’ Lead MASP-3 Inhibitor OMS906 Shows Multi-Week Blockade of the Alternative Pathway
-- Non-Human Primate Data Support Advancing to Clinic -- SEATTLE--(BUSINESS WIRE)--Nov. 10, 2016-- Omeros Corporation (NASDAQ: OMER) today announced pharmacokinetic and pharmacodynamic data from the evaluation of OMS906 in non-human primates. OMS906 inhibits mannan-binding lectin-associated serine protease-3 (MASP-3), the protein critical to activation of the alternative pathway of complement (APC), a key component of the immune system. MASP-3... 
 Printer Friendly Version
11/09/16Omeros Corporation Reports Third Quarter 2016 Financial Results
-- Conference Call Today at 4:30 p.m. ET -- SEATTLE--(BUSINESS WIRE)--Nov. 9, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as fina... 
 Printer Friendly Version
11/07/16Omeros Corporation to Announce Third Quarter 2016 Financial Results on November 9, 2016
SEATTLE--(BUSINESS WIRE)--Nov. 7, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the company will issue its third quarter 2016 financial results for the period ended September 30, 2... 
 Printer Friendly Version
11/04/16Omeros Announces Completion of Initial Funding under $125 Million Credit Facility
SEATTLE--(BUSINESS WIRE)--Nov. 4, 2016-- Omeros Corporation (NASDAQ: OMER) today announced that it has completed the initial funding under its senior secured credit facility with affiliates of CRG LP, a healthcare-focused investment firm, consisting of an $80 million term loan. The company used approximately $76 million of the loan proceeds to repay its obligations under its previous credit facility and the remaining net proceeds will be used for general... 
 Printer Friendly Version
11/03/16Omeros Files Orphan Drug Application for OMS721 in Immunoglobulin A Nephropathy
-- Omeros Continues to Expand Orphan Indications for OMS721 -- SEATTLE--(BUSINESS WIRE)--Nov. 3, 2016-- Omeros Corporation (NASDAQ: OMER) today announced that it has filed an application for orphan drug designation with the U.S. Food and Drug Administration (FDA) for OMS721 in the treatment of immunoglobulin A (IgA) nephropathy (also known as Berger’s disease). IgA nephropathy leads to end-stage renal disease in up to 40 percent of patients. Orphan ... 
 Printer Friendly Version
11/02/16Omeros Announces Positive Data from Phase 2 Clinical Trial Evaluating PPAR-Gamma Agonist in Heroin Users Treated with Buprenorphine/Naloxone
– Decreases Craving and Anxiety in Heroin-Dependent Patients – SEATTLE--(BUSINESS WIRE)--Nov. 2, 2016-- Omeros Corporation (NASDAQ: OMER) today announced positive results from a Phase 2 clinical trial evaluating the effects of a peroxisome proliferator-activated receptor (PPAR)-gamma agonist in heroin-dependent subjects. The trial was designed and conducted by Dr. Sandra Comer and her colleagues at the Division on Substance Abuse, New York State ... 
 Printer Friendly Version
10/31/16Omeros Requests Fast Track Designation for OMS721 for the Treatment of IgA Nephropathy
-- Phase 3 Clinical Program Planned for 2017 -- SEATTLE--(BUSINESS WIRE)--Oct. 31, 2016-- Omeros Corporation (NASDAQ: OMER) today announced that it has requested fast track designation from the U.S. Food and Drug Administration (FDA) for the development of OMS721 for the treatment of patients with immunoglobulin A (IgA) nephropathy (also known as Berger’s disease). The company recently reported positive data (p = 0.017) from the company’s Phas... 
 Printer Friendly Version
10/27/16Omeros Announces $125 Million New Credit Facility
SEATTLE--(BUSINESS WIRE)--Oct. 27, 2016-- Omeros Corporation (NASDAQ: OMER) today announced that it has entered into a senior credit facility with CRG LP, a healthcare-focused investment firm, to retire the company’s existing credit facility, minimizing restricted cash requirements and providing additional working capital for its advancing pipeline. The new credit facility consists of an $80 million term loan to be drawn by the company wit... 
 Printer Friendly Version
10/20/16Omeros Announces Positive Data from OMS721 Phase 2 Trial in Patients with Stem Cell Transplant-Associated Thrombotic Microangiopathy
-- Targeted Indications for the Company’s MASP-2 Inhibitor Continue to Expand -- SEATTLE--(BUSINESS WIRE)--Oct. 20, 2016-- Omeros Corporation (NASDAQ: OMER) today announced positive results in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) from the company's Phase 2 clinical trial of OMS721 in TMAs, with clinically meaningful improvement in measures of red blood cell destruction, specifically ... 
 Printer Friendly Version
10/19/16Omeros Announces Positive Data from Phase 2 Clinical Trial Evaluating PPAR-gamma Agonist in Cocaine Abuse
-- Decreases Craving and Protects Brain White Matter Integrity -- SEATTLE--(BUSINESS WIRE)--Oct. 19, 2016-- Omeros Corporation (NASDAQ: OMER) today announced positive results from a Phase 2 clinical trial evaluating the effects of a peroxisome proliferator-activated receptor (PPAR)-gamma agonist in patients with cocaine use disorder (CUD). The trial, designed and conducted by Joy M. Schmitz, Ph.D. and her colleagues at the Center for Neurobehavioral ... 
 Printer Friendly Version
10/17/16Omeros Announces Positive Data from OMS721 Phase 2 Clinical Trial in Renal Diseases
-- Pursuing Breakthrough Therapy Designation in IgA Nephropathy (Berger’s Disease) -- SEATTLE--(BUSINESS WIRE)--Oct. 17, 2016-- Omeros Corporation (NASDAQ: OMER) today announced positive data from the company’s Phase 2 clinical trial of OMS721 for the treatment of kidney disorders, none of which currently have an approved treatment and all of which frequently lead to end-stage renal disease and dialysis. Statistical significance (p ≤ 0.017) wa... 
 Printer Friendly Version
09/08/16Omeros’ MASP-2 Antibody Preserves Brain Tissue and Function in Stroke Models
-- Data Published in Journal of Neuroinflammation -- SEATTLE--(BUSINESS WIRE)--Sep. 8, 2016-- Omeros Corporation (NASDAQ: OMER) today announced results from its OMS721 complement program. OMS721 is Omeros’ lead antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2). In well-established animal models of ischemic brain injury or stroke, MASP-2 deficiency or inhibition significantly limited brain infarct size and protected... 
 Printer Friendly Version
08/12/16Omeros to Present at the 2016 Wedbush PacGrow Healthcare Conference
SEATTLE--(BUSINESS WIRE)--Aug. 12, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 2016 Wedbush ... 
 Printer Friendly Version
08/11/16Omeros Announces Pricing of Public Offering of Common Stock
SEATTLE, Aug. 11, 2016 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) announced today the pricing of a $40 million underwritten public offering of its common stock at a price to the public of $11.50 per share, before deducting underwriting discounts and commission and other estimated offering expenses. The offering is expected to close on or about August 16, 2016, subject to the satisfaction of customary closing conditions. Cantor Fitzgerald & Co. is acting as the sole underwriter for ... 
 Printer Friendly Version
08/10/16Omeros’ Lead MASP-3 Inhibitor OMS906 Demonstrates Efficacy in Paroxysmal Nocturnal Hemoglobinuria Model
-- Shows Substantial Advantage over C5 Inhibitor -- SEATTLE--(BUSINESS WIRE)--Aug. 10, 2016-- Omeros Corporation (NASDAQ: OMER) today announced results from its OMS906 complement program. OMS906 is Omeros’ lead antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3). In a well-established animal model associated with paroxysmal nocturnal hemoglobinuria (PNH), OMS906 significantly improved the survival of red blood cells ... 
 Printer Friendly Version
08/10/16Omeros Announces Public Offering of Common Stock
SEATTLE, Aug. 10, 2016 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced an agreement to sell $40 million of shares of its common stock to Cantor Fitzgerald & Co., as the sole underwriter, in a registered underwritten public offering. Omeros intends to use the net proceeds of the offering for general corporate purposes, including funding research and development expenses for its clinical OMS721 program and clinical trials, pre-clinical studies, manufacturing development and o... 
 Printer Friendly Version
08/09/16Omeros Corporation Reports Second Quarter 2016 Financial Results
-- Conference Call Today at 4:30 p.m. ET -- SEATTLE--(BUSINESS WIRE)--Aug. 9, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as fina... 
 Printer Friendly Version
08/04/16Omeros Corporation to Announce Second Quarter 2016 Financial Results on August 9, 2016
SEATTLE--(BUSINESS WIRE)--Aug. 4, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the company will issue its second quarter 2016 financial results for the period ended June 30, 2016,... 
 Printer Friendly Version
08/04/16Omeros’ Lead MASP-3 Inhibitor OMS906 Demonstrates Blockade of the Alternative Pathway of Complement System
-- Shows Marked Efficacy in Model of Arthritis -- SEATTLE--(BUSINESS WIRE)--Aug. 4, 2016-- Omeros Corporation (NASDAQ: OMER) today announced results from its OMS906 complement program. OMS906 is Omeros’ lead antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the protein activator of the alternative pathway of complement (APC). OMS906 significantly reduced both incidence and severity of disease in a well-established... 
 Printer Friendly Version
07/28/16Omeros Corporation Confirms OMS721 Phase 3 Development Plan with European Medicines Agency
-- One Single-Arm, Open-Label Phase 3 Pivotal Trial Planned to Support Approval in Both Europe and the U.S. -- SEATTLE, July 28, 2016 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has received scientific advice from the European Medicines Agency (EMA) in connection with the company's OMS721 Phase 3 program for the treatment of atypical hemolytic uremic syndrome (aHUS). Based on this EMA advice, the company plans to run the same, single Phase 3 clinical program to... 
 Printer Friendly Version
07/07/16Omeros to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference
SEATTLE--(BUSINESS WIRE)--Jul. 7, 2016-- Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the Cantor F... 
 Printer Friendly Version
06/29/16Omeros Corporation Announces Completion of Patient Enrollment in Pediatric Trial of OMIDRIA®
-- Successful Completion Expected to Lead to Additional Market Exclusivity -- SEATTLE--(BUSINESS WIRE)--Jun. 29, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that it has com... 
 Printer Friendly Version
05/17/16Omeros Announces Debt Financing Transaction for $20 Million in Additional Funds
SEATTLE--(BUSINESS WIRE)--May 17, 2016-- Omeros Corporation (NASDAQ: OMER) (the “Company”) today announced that it has entered into an amendment to its existing credit facility with Oxford Finance LLC (“Oxford”) and East West Bank (“East West”) to provide the Company with an additional $20 million in unrestricted cash by funding the remaining tranches of the facility. Omeros will issue warrants to the lenders, exercisable for seven years for up to 100,60... 
 Printer Friendly Version
05/10/16Omeros Corporation Reports First Quarter 2016 Financial Results
-- Conference Call Today at 9:00 a.m. ET -- SEATTLE--(BUSINESS WIRE)--May 10, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as fina... 
 Printer Friendly Version
05/10/16Leonard M. Blum Joins Omeros to Lead Business and Commercial Activities
SEATTLE--(BUSINESS WIRE)--May 10, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced the hiring of Leonard Blum as chief business and commercial officer. Mr. Blum is leading the company’s ... 
 Printer Friendly Version
05/10/16Omeros Corporation Announces Exclusive Middle East Distribution Agreement for OMIDRIA®
-- Initiates International Market Expansion -- SEATTLE--(BUSINESS WIRE)--May 10, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced entry into an exclusive supply and distribution... 
 Printer Friendly Version
05/04/16Omeros Corporation to Announce First Quarter 2016 Financial Results on May 10, 2016
SEATTLE--(BUSINESS WIRE)--May 4, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the company will issue its first quarter 2016 financial results for the period ended March 31, 2016, ... 
 Printer Friendly Version
04/26/16Omeros Corporation Announces Independent Studies with OMIDRIA® to Be Presented at Upcoming Ophthalmology Congresses
-- Studies Assessed Key Surgical Outcome Measures Including Complication Rates -- SEATTLE--(BUSINESS WIRE)--Apr. 26, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that new re... 
 Printer Friendly Version
04/20/16Patient Dosing Initiated for OMS721 Phase 2 Program in Renal Diseases
-- Study Provides an Opportunity for Breakthrough Therapy Designation and Subsequent Accelerated Approval -- SEATTLE--(BUSINESS WIRE)--Apr. 20, 2016-- Omeros Corporation (NASDAQ: OMER) today announced initiation of patient dosing in its OMS721 Phase 2 program in corticosteroid-dependent renal diseases. The Phase 2 clinical trial of OMS721, the company’s lead mannan-binding lectin-associated serine protease-2 (MASP-2) inhibitor being developed ... 
 Printer Friendly Version
04/07/16Omeros to Present at the 15th Annual Needham Healthcare Conference
SEATTLE--(BUSINESS WIRE)--Apr. 7, 2016-- Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 15th Ann... 
 Printer Friendly Version
03/08/16Omeros Corporation Initiates its Phase 3 Program for OMS721 in aHUS Following Meeting with FDA
-- Single Pivotal Study Needed for Phase 3 -- SEATTLE--(BUSINESS WIRE)--Mar. 8, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that it has initiated its Phase 3 OMS721 program... 
 Printer Friendly Version
03/07/16Omeros Corporation Reports Fourth Quarter and Year-End 2015 Financial Results
Conference Call Tomorrow, March 8, at 9:00 a.m. ET SEATTLE--(BUSINESS WIRE)--Mar. 7, 2016-- Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well a... 
 Printer Friendly Version
03/03/16Omeros to Present at the Cowen and Company 36th Annual Health Care Conference
SEATTLE--(BUSINESS WIRE)--Mar. 3, 2016--   Omeros Corporation  (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the Cowen and Company 36th Annual Health C... 
 Printer Friendly Version
03/02/16Omeros Corporation to Announce Fourth Quarter and Year-End 2015 Financial Results on March 8, 2016
SEATTLE--(BUSINESS WIRE)--Mar. 2, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the company will issue its fourth quarter and year-end 2015 financial results for the period ended ... 
 Printer Friendly Version
02/24/16Physicians Increasingly Seek Access to OMS721 Compassionate Use Program
-- OMS721 Requested for Finnish Patient Not Adequately Responsive to Soliris® -- SEATTLE--(BUSINESS WIRE)--Feb. 24, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced further expa... 
 Printer Friendly Version
01/15/16Disclosure of Omidria Post-Launch Study Findings to Occur at Hawaiian Eye and Retina Conference
SEATTLE--(BUSINESS WIRE)--Jan. 15, 2016-- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that Omidria® (phenylephrine and ketorolac injection) 1% / 0.3% will be the focus of a series of ... 
 Printer Friendly Version
01/06/16Omeros Announces $70 Million New Credit Facility and Conversion of Contract Sales Force to In-House Team
SEATTLE--(BUSINESS WIRE)--Jan. 6, 2016-- Omeros Corporation (NASDAQ:OMER) today announced that it has closed a non-dilutive senior credit facility with Oxford Finance and East West Bank. The new credit facility consists of a $50.0 million term loan drawn by the company at closing and the ability, subject to the satisfaction of certain conditions including achievement of certain net revenue milestones for the company’s product Omidria® (phenylephri... 
 Printer Friendly Version